A4i is a patent pending, validated, digital therapeutic with a regulatory pathway for complex behavioral health. A4i's first indication is outcomes improvements and relapse-risk identification in schizophrenia/psychosis spectrum illnesses. A joint venture between Canada's largest mental health teaching hospital and MEMOTEXT precision global digital therapeutics platform, A4i shows significant improvements in several outcome domains related to schizophrenia and psychoses recovery.

A4i Inc. (App4Independence) Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total